Abstract:
The present invention relates to a composition comprising 3-caffeoyl-4-dihydrocaffeoylquinic acid for preventing or treating fatty liver or obesity. The 3-caffeoyl-4-dihydrocaffeoylquinic acid has an excellent effect of inhibiting the synthesis of fatty acids, cholesterol, and triglycerides in a fatty liver cell model, increases the activity of AMPK which is associated with lipogenesis suppression, and has an excellent effect of inhibiting activities of SREBP-1 and FAS which are transcription factors of fatty acid synthesis, thus can be usefully applied as a therapeutic agent for fatty liver or obesity.
Abstract:
PURPOSE: An anticancer composition comprising mollugin is provided to use as a therapeutic agent for cancer patients who have tolerance to existing anticancer drugs by having an excellent effect of killing multidrug resistance cancer cells. CONSTITUTION: An anticancer composition having an effect of killing multidrug resistance cancel cells comprises mollugin of chemical formula 1. The multidrug resistance cancer cells are cancer cells which express multidrug resistance 1 (MDR1). The composition increases activation of AMP-activated protein kinase (AMPK). An anticancer drung is added to the composition. The mollugin is comprised in the composition in a ratio of 0.001-99 wt%.
Abstract:
PURPOSE: A composition for preventing or treating breast cancer and ovarian cancer, comprising mollugin is provided to have excellent effect of killing cancer cells. CONSTITUTION: A composition for preventing or treating breast cancer and ovarian cancer comprises mollugin of chemical formula 1. The breast cancer or ovarian cancer is a cancer that the gene of human epidermal growth factor receptor 2 (HER2) is overexpressed. The composition suppresses HER2/Akt/sterol regulatory element binding proteins (SREBPs). A pharmaceutical composition for preventing or treating breast cancer and ovarian cancer comprises the mollugin and a pharmaceutical exipient. The mollugin in the pharmaceutical composition is comprised in a ratio of 0.001-99.9 wt%.
Abstract:
본 발명은 3-카페오일-4-다이하이드로카페오일 퀴닉산을 함유하는 지방간 또는 비만의 예방 또는 치료용 조성물에 관한 것으로서, 상기 3-카페오일-4-다이하이드로카페오일 퀴닉산은 지방간 모델 세포에서 지방산, 콜레스테롤 및 트리글리세리드의 합성을 억제하는 효과가 우수하고, 지방 생성 억제와 관련이 있는 AMPK의 활성을 높이며, 지방산 합성의 전사인자인 SREBP-1 및 FAS의 활성을 억제하는 효과가 뛰어나기에, 지방간 또는 비만의 치료제로서 용이하게 이용될 수 있다.